A case for immediate-release niacin

Heart and Lung: Journal of Acute and Critical Care

Volumn 41, Issue 1, 2012, Pages 95-98

  Bassan, Mayer ^a  

^a NONE   (Israel)

Author keywords

HDL; Hepatotoxicity; Niacin

Indexed keywords

NICOTINIC ACID; NON PRESCRIPTION DRUG; PROPRANOLOL; SIMVASTATIN;

AGED; ANGINA PECTORIS; ARTICLE; CASE REPORT; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG RELEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; HUMAN; IMMEDIATE DRUG RELEASE; MALE; NAUSEA; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; SLOW DRUG RELEASE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84455196332     PISSN: 01479563     EISSN: 15273288     Source Type: Journal    
DOI: 10.1016/j.hrtlng.2010.07.019     Document Type: Article

References (18)

1. Superko H.R., King S. Lipid management to reduce cardiovascular risk: a new strategy is required. Circulation 2008, 117:560-568.
2. Maron D.J., Fazio S., Linton M.F. Current perspectives on statins. Circulation 2000, 101:207-213.
3. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M., Kastelein J.J., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. NEngl J Med 2008, 359:2195-2207.
4. Knopp R.H. Drug treatment of lipid disorders. NEngl JMed 1999, 341:498-511.
5. Lee J.M., Robson M.D., Yu L.M., Shirodaria C.C., Cunnington C., Kylintireas I., et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. JAm Coll Cardiol 2009, 54:1787-1794.
6. Taylor A.J., Villines T.C., Stanek E.J., Devine P.J., Griffen L., Miller M., et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. NEngl J Med 2009, 361:2113-2122.
7. Brown B.G., Zhao X.Q., Chait A., Fisher L.D., Cheung M.C., Morse J.S., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. NEngl J Med 2001, 345:1583-1592.
8. Canner P.L., Berge K.G., Wenger N.K., Stamler J., Friedman L., Prineas R.J., et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. JAm Coll Cardiol 1986, 8:1245-1255.
9. Lasagna L. Over-the-counter niacin. JAMA 1994, 271:709-710.
10. Christensen N.A., Achor W.P., Berge K.G., Mason H.L. Nicotinic acid treatment of hypercholesterolemia. Comparison of plain and sustained-action preparations and report of two cases of jaundice. JAMA 1961, 177:546-550.
11. McKenney J.M., Proctor J.D., Harris S., Chinchili V.M. Acomparison of the efficacy and toxic effects of sustained- vs. immediate-release niacin in hypercholesterolemic patients. JAMA 1994, 271:672-677.
12. Knopp R.H., Ginsberg J., Albers J.J., Hoff C., Ogilvie J.T., Warnick G.R., et al. Contrasting effects of unmodified and time- release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 1985, 34:642-650.
13. Henkin Y., Oberman A., Hurst D.C., Segrest J.P. Niacin revisited: clinical observations on an important but underutilized drug. Am J Med 1991, 91:239-246.
14. Ashen M.D., Blumenthal R.S. Low HDL cholesterol levels. NEngl J Med 2005, 353:1252-1260.
15. Illingworth D.R., Stein E.A., Mitchel Y.B., Dujovne C.A., Frost P.H., Knopp R.H., et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. Arch Intern Med 1994, 154:1586-1595.
16. Mills E., Prousky J., Raskin G., Gagnier J., Rachlis B., Montori V.M., et al. The safety of over-the-counter niacin. A randomized placebo-controlled trial. BMC Clin Pharmacol 2003, 3:4.
17. Maccubbin D., Koren M.J., Davidson M., Gavish D., Pasternak R.C., Macdonell G., et al. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol 2009, 104:74-81.
18. Parsons W.B. Cholesterol control without diet 1998, Lilac Press, Scottsdale, AZ.